DUBLIN–(BUSINESS WIRE)–The “Computer-Aided Drug Discovery Market By Type, By Therapeutic Area, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2030” report has been added to ResearchAndMarkets.com’s offering.
The global computer-aided drug discovery market was valued at $2,940.9 million in 2021 and is projected to reach $7,504.7 million by 2030, growing at a CAGR of 11.48% from 2022 to 2030.
The prevalence of chronic diseases, such as cardiovascular disease, has risen dramatically in recent years. According to the World Health Organization (WHO), the United Nations (UN) specialized agency responsible for international public health, the number of CVD patients may reach 23 million by the end of 2030. Furthermore, according to Premier, Inc., a notable healthcare improvement company, the demand for novel drugs for the treatment of CVD conditions has skyrocketed as a result of the COVID-19 crisis. The facts and figures presented above show that the need for the development of new drug molecules is expected to rise, which may have a positive impact on the global computer-aided drug discovery market during the analysis period.
However, lack of skilled labor for operating computer aided drug discovery solutions may hamper the global market growth. Also, lower product penetration in the emerging economies is also restraining the global computer-aided drug discovery market.
Emerging concepts such as artificial intelligence (AI) and big data in computer-aided drug discovery, on the other hand, may drive the market over the forecast period. Many aspects of drug discovery can benefit from artificial intelligence, including drug design, chemical synthesis, drug screening, drug repurposing, and polypharmacology.
The global computer-aided drug discovery market is segmented on the basis of type, therapeutic area, end-user, and region. By type, the market is classified into structure-based drug design (SBDD), ligand-based drug design (LBDD), and sequence-based approaches. By therapeutic area, the analysis has been divided into oncology, neurology, cardiovascular disease, respiratory disease, diabetes, and others. By end-user, the market has been divided into pharmaceutical companies, biotechnology companies and research laboratories. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players profiled in this report include BOCSCI Inc., Bioduro-Sundia, Schrodinger, Inc., Aragen Life Sciences Pvt. Ltd., Aris Pharmaceuticals, Inc, Charles River Laboratories, Bayer AG, AstraZeneca, and Albany Molecular Research Inc. (AMRI).
Key Market Segments
By Type
Structure Based Drug Design
Ligand-Based Drug Design
Sequence-Based Approaches
By Therapeutic Area
Oncology
Neurology
Cardiovascular Disease
Respiratory Disease
Diabetes
Others
By End User
Pharmaceutical Companies
Biotechnology Companies
Research Laboratories
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest Of Asia Pacific
LAMEA
Brazil
Saudi Arabia
UAE
South Africa
Rest of LAMEA
Key Market Players
charles river laboratories
BOC Sciences
Bioduro-Sundia
Schrodinger, Inc.
Aragen Life Sciences Pvt. Ltd.
Aris Pharmaceuticals, Inc.
Bayer AG
AstraZeneca plc
Albany Molecular Research Inc. (AMRI)
Key Topics Covered:
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE
CHAPTER 5: COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA
CHAPTER 6: COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER
CHAPTER 7: COMPUTER-AIDED DRUG DISCOVERY MARKET, BY REGION
CHAPTER 8: COMPANY LANDSCAPE
CHAPTER 9: COMPANY PROFILES
For more information about this report visit https://www.researchandmarkets.com/r/51j4yg
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
